We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TNC:NYSETennant Company Analysis

Data as of 2026-08-01 - not real-time

$84.03

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Tennant Company (TNC) trades at $84.03, just below its 20‑day SMA (86.08) and 50‑day SMA (86.44), with a neutral price trend but a bearish MACD histogram (-0.37) and RSI at 44, suggesting limited upside momentum. The stock’s forward PE of 13.1 contrasts sharply with a trailing PE of 50, far above the industry average of 30.9, while a discounted‑cash‑flow model values the shares around $26, highlighting a stark valuation disconnect. Meanwhile, the company faces a federal securities investigation tied to a problematic ERP rollout, adding regulatory headwinds to already thin operating margins (1.7% gross, 2.5% profit) and a modest revenue growth rate of 2.7%.
The balance sheet shows a debt‑to‑equity of 73.6% and a payout ratio of 72%, raising concerns about dividend sustainability despite a 1.48% yield. Volatility is elevated at 32% over the past 30 days, though beta (0.81) suggests lower market sensitivity. With support near $78.25 and resistance at $89.97, the stock sits in a narrow range while investors weigh the upside to analyst targets (~$94) against the heavy valuation and operational risks.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Federal securities investigation increasing regulatory risk
  • Bearish MACD and neutral trend limiting upside
  • Current valuation (PE 50) far above industry norms

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential operational recovery after ERP issues
  • Dividend yield of 1.48% may attract income seekers
  • Analyst target price (~$94) implies modest upside

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Sustained high leverage and weak profitability
  • Persistent valuation gap (DCF $26 vs market $84)
  • Long‑term regulatory and execution risk

Key Metrics & Analysis

Financial Health

Revenue Growth2.70%
Profit Margin2.55%
P/E Ratio50.0
ROE5.33%
ROA2.99%
Debt/Equity73.64
P/B Ratio2.7
Op. Cash Flow$34.2M
Free Cash Flow$52.5M
Industry P/E30.9

Technical Analysis

TrendNeutral
RSI43.9
Support$78.25
Resistance$89.97
MA 20$86.08
MA 50$86.44
MA 200$78.17
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair Value$26.20
Target Price$93.50
Upside/Downside11.27%
GradeOvervalued
TypeValue
Dividend Yield1.48%

Risk Assessment

Beta0.81
Volatility32.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.